Description: Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its clinical pipelines include adoptive cell therapy (ACT) and TCR biscpecifics (TCER™). Its therapeutic approaches are ACTengine, Next Generation ACT, and TCER. The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.
Home Page: www.immatics.com
IMTX Technical Analysis
Paul-Ehrlich-Strasse 15
Tübingen,
72076
Germany
Phone:
49 7071 5397 0
Officers
| Name | Title |
|---|---|
| Dr. Harpreet Singh Ph.D. | CEO, MD, Member of Management Board & Supervisory Director |
| Dr. Hans-Georg Rammensee Ph.D. | Co-Founder & Member of the Scientific Advisory Board |
| Dr. Toni Weinschenk Ph.D. | Co-Founder & Chief Innovation Officer |
| Mr. Arnd Christ MBA | Chief Financial Officer |
| Mr. Steffen Walter Ph.D. | Chief Technology Officer |
| Mr. Edward A. Sturchio | Gen. Counsel & Sec. |
| Ms. Anja Heuer B.Sc. | Director of Corp. Communications |
| Ms. Tamara Louw M.B.A., P.H.R. | Sr. Director of HR |
| Dr. Carsten Reinhardt M.D., Ph.D. | Chief Devel. Officer |
| Dr. Rainer Kramer Ph.D. | Chief Bus. Officer & Site Head Munich |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 15.5804 |
| Price-to-Book MRQ: | 6.1801 |
| Price-to-Sales TTM: | 4.7026 |
| IPO Date: | 2020-07-02 |
| Fiscal Year End: | December |
| Full Time Employees: | 382 |